Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 12,232 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Meningococcal Disease
Interventions: MenABCWY, Placebo, MenACWY; Biological · Other
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more

Conditions: Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Interventions: QR-313, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 4 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more

Conditions: Multiple Myeloma
Interventions: Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Prednisone, Quality-of-Life Assessment, Thalidomide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 389
States / cities: Mobile, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 255 more

Conditions: Wounds and Injuries, Multiple Trauma, Disorder of Fluid Balance
Interventions: Plasmalyte A, Normal Saline; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hepatitis C
Interventions: SOF, RBV, Peg-IFN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Riverside, California • San Diego, California • San Francisco, California + 19 more

Conditions: Joint Instability
Interventions: Dr. Scholl's Prototype Ankle Brace, Dr. Scholl's Prototype Knee Brace; Device
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Richardson, Texas

Conditions: Pediatric Obesity, Pediatric Overweight
Interventions: Multifamily weight management intervention; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 8 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
Interventions: Active SAINT Stimulation, Sham SAINT Stimulation; Device
Lead sponsor: Magnus Medical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Iowa City, Iowa • Manhattan, New York • Charleston, South Carolina + 1 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: beclomethasone dipropionate; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 5 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Asthma
Interventions: QGE031, Omalizumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Fresno, California • Hawaiian Gardens, California • Riverside, California + 19 more

Conditions: Healthy, Hepatic Insufficiency
Interventions: BI 685509, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Survey; Other
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Duchenne Muscular Dystrophy
Interventions: AVI-4658 (Eteplirsen), Placebo; Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 7 Years to 13 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Myeloma
Interventions: Mapatumumab, Bortezomib; Biological · Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 8
States / cities: Scottsdale, Arizona • La Jolla, California • Lecanto, Florida + 5 more

Conditions: Healthy, no Evidence of Disease, Prostate Cancer
Interventions: lycopene, pharmacological study; Dietary Supplement · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: biological samples; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: North Haven, Connecticut

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: N-803; Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Minneapolis, Minnesota • St Louis, Missouri • Buffalo, New York + 1 more

Conditions: Asthma
Interventions: Multi-Component Technology Based Intervention; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Hypertriglyceridemia
Interventions: Diazoxide choline; Drug
Lead sponsor: Essentialis, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Advanced Lung Cancer, Dyspnea
Interventions: Dyspnea Intervention, Enhanced Usual Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Coral Gables, Florida • Boston, Massachusetts

Conditions: Barth Syndrome
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 5 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome
Interventions: Pentostatin, Sirolimus, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplant (HSCT), Th2 rapa cells, Donor Lymphocyte Harvest, Induction Therapy, GVHD prophylaxis, Donor Hematopoietic Stem Cell Harvest; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Aurora, Colorado • Worcester, Massachusetts • Ann Arbor, Michigan + 4 more

Conditions: Multiple Myeloma
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Goodyear, Arizona • Anaheim, California + 49 more

Search by objective public record fields.

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability

Reducing Barriers to Behavior Change Among Youth With Pediatric Overweight and Obesity

The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Survey of Patients Taking IOP-Lowering Eye Drops

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Lycopene in Healthy Male Participants

Identifying and Characterizing Preclinical MS

QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

Detroit Young Adult Asthma Project

Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations

Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)